RE:Merck’s Keytruda brings in $21 Billion. <p>
And The Keytruda patent(s) begin running out in 2028. Merck revenues were $43 billion in 2021 and Keytruda was $15 billion of that. Merck has been out there doing all sorts of combo trials in the hopes of finding one or more that will enable it to extend its patents.
Note that the vaccine companies are responsible for ~45% of the FDA's annual budget (and that of the CDC, too). If you ever wonder who's in charge, follow the money.
Big Pharma derived $143 billion from the sale of oncology drugs in 2021 alone.
I don't see them (Big Pharma and/or vaccine makers) willingly making room at the crowded trough for this up and coming new therapy from a mini biotech, and a Canadian one at that. Just a couple considerations that the CEO will have to manuveur through, and a couple factoids that tell me that RDW lacks the chops for the job.
The ASCO GU cancer poster correctly indicates this therapy is to "destroy" cancer cells, bacteria, and viruses. It's not being billed as a "cure" as the use of that term in anything other than fund-raising has been discouraged for two decades now.